Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 8/20 | 0.44 |
| ▸ | APP | P05067 | 2/20 | 0.42 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | RXRB | P28702 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17488180 | 0.83 | MAOB (0.59) | CCR5APPIDO1MAOB | |
| SCHEMBL4288596 | 0.82 | PLAU (0.46) | NPC1SLC6A4LMNA | |
| SCHEMBL510525 | 0.79 | MAOB (0.45) | CCR5APPIDO1MAOBNPC1 | |
| SCHEMBL11182657 | 0.79 | NPC1 (0.47) | APPIDO1MAOBNPC1HTT | |
| SCHEMBL17488179 | 0.79 | TDP1 (0.47) | CCR5MAOBRAB9A | |
| SCHEMBL18429708 | 0.76 | APP (0.59) | APPIDO1 | |
| SCHEMBL510047 | 0.76 | MAOB (0.49) | CCR5APPIDO1MAOBNPC1 | |
| SCHEMBL5652119 | 0.76 | MAOB (0.47) | APPIDO1MAOBNPC1RAB9A | |
| SCHEMBL18256806 | 0.76 | LMNA (0.42) | APPIDO1MAOBHTTRAB9A | |
| SCHEMBL17128821 | 0.76 | NPC1 (0.51) | APPIDO1MAOBNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9102621-B2 | Acyl sulfonamide compounds | PFIZER LIMITED (GB) | 2015-08-11 | — | — | US | disclosed |
| US-9102621-B2 | Acyl sulfonamide compounds | PFIZER LIMITED (GB) | 2015-08-11 | — | — | US | disclosed |
| US-9102621-B2 | Acyl sulfonamide compounds | PFIZER LIMITED (GB) | 2015-08-11 | — | — | US | disclosed |
| EP-2593431-B1 | N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | PFIZER LTD (GB) | 2014-11-19 | — | — | EP | disclosed |
| EP-2593431-B1 | N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | PFIZER LTD (GB) | 2014-11-19 | — | — | EP | disclosed |
| EP-2593431-A2 | CHEMICAL COMPOUNDS | Pfizer Limited (GB) | 2013-05-22 | — | — | EP | disclosed |
| US-20130109708-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2013-05-02 | — | — | US | disclosed |
| US-20130109708-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2013-05-02 | — | — | US | disclosed |
| US-20130109708-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2013-05-02 | — | — | US | disclosed |
| WO-2012007869-A2 | CHEMICAL COMPOUNDS | PFIZER LIMITED (GB) | 2012-01-19 | — | — | WO | disclosed |
| WO-2012007869-A2 | CHEMICAL COMPOUNDS | PFIZER LIMITED (GB) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109708-A1 | Chemical Compounds | SCN1A, SCN1B, SCN7A | CCR5 2873/4885APP 2945/4885IDO1 2809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.